Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Isoquinoline

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Isoquinoline?

Isoquinoline is an investigational drug.

There have been 11 clinical trials for Isoquinoline. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2018.

The most common disease conditions in clinical trials are Cysticercosis, HIV Infections, and Taeniasis. The leading clinical trial sponsors are National Institute of Mental Health (NIMH), Tianjin Anding Hospital, and xiaohua li.

There are nine hundred and ninety-five US patents protecting this investigational drug and nine international patents.

Recent Clinical Trials for Isoquinoline
Comparation of Berberine and Metformin for the Treatment for MS in Schizophrenia PatientsTianjin Anding HospitalPhase 4
Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail ApproachNational Center for Complementary and Integrative Health (NCCIH)Early Phase 1
Assessing Goldenseal-drug Interactions Using a Probe Drug Cocktail ApproachWashington State UniversityEarly Phase 1

See all Isoquinoline clinical trials

Clinical Trial Summary for Isoquinoline

Top disease conditions for Isoquinoline
Top clinical trial sponsors for Isoquinoline

See all Isoquinoline clinical trials

US Patents for Isoquinoline

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Isoquinoline   Start Trial Production method of 1, 2, 4-triazole compound Sumitomo Chemical Company, Limited (Tokyo, JP)   Start Trial
Isoquinoline   Start Trial Substituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridines as factor XIa inhibitors Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
Isoquinoline   Start Trial Crystalline dimethyl 3-(benzyloxy)-1-(2,2-dimethoxyethyl)-4-oxo-1,4-dihydropyridine-2,5-dicarb- oxylate Shionogi & Co., Ltd (JP)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.